There is little to no exploration of oxaliplatin being used as a therapeutic agent for AML, liver (36), prostate (37), and testicular (38) cancers, and perhaps the upregulation of LAT3 observed in these tumor tissues could facilitate an initial response. This evidence concerns the gene SLC43A1 and neoplasm.